Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious…